Performance-Linked Reimbursement and the Uncertainty of Novel Drugs-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Performance-Linked Reimbursement and the Uncertainty of Novel Drugs

Published:2022-01 Issue:1 Volume:15 Page:
ISSN:1941-7713
Container-title:Circulation: Cardiovascular Quality and Outcomes
language:en
Short-container-title:Circ: Cardiovascular Quality and Outcomes

Author:

Rand Leah Z.¹^ORCID,Kesselheim Aaron S.¹^ORCID

Affiliation:

1. Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, and the Harvard Medical School Center for Bioethics, Boston, MA.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference10 articles.

1. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval

2. Revisiting FDA Approval of Aducanumab

3. Perks and Pitfalls of Performance-Linked Reimbursement for Novel Drugs: The Case of Sacubitril-Valsartan

4. Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment?

5. Beyond the Randomized Clinical Trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions;American Society of Clinical Oncology Educational Book;2023-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP